Advances on the BRAF Front in Colorectal Cancer [In the Spotlight]

Summary: Colorectal cancer with BRAF^V600E mutation can be effectively treated with combination approaches involving inhibition of BRAF, MEK, and EGFR proteins. However, activation of the MAPK pathway, often due to emergence of previously undetected molecular alterations, ultimately leads to adaptive therapeutic resistance. Novel combination strategies combining inhibition of BRAF, ERK, and EGFR can be used to prevent MAPK pathway–driven resistance and warrant further investigation. Cancer Discov; 8(4); 389–91. ©2018 AACR.

See related article by Corcoran et al., p. 428.

See related article by Hazar-Rethinam et al., p. 417.

from Cancer via ola Kala on Inoreader https://ift.tt/2JbIK6N
via IFTTT